GlassScriptPhysician profile
Stephanie Lee
NPI 1437547288
$8,809.96
in general payments reported to CMS, 2019-2025
31 companies · $1,147 in 2025
The $1,147 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,105 · 2022: $2,132 · 2023: $2,459 · 2024: $967 · 2025: $1,147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,368 · Education: $205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,368.11 |
| Education | $204.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,453.15 | 2021-2025 | |
| Janssen Biotech, INC. | $738.43 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| E.R. Squibb & Sons, L.L.C. | $609.83 | 2022-2025 | Sotyktu |
| Dermavant Sciences, INC. | $588.47 | 2022-2024 | Vtama |
| Lilly USA, LLC | $560.77 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Sun Pharmaceutical Industries INC. | $542.86 | 2021-2024 | Blu-U, Ilumya, Winlevi |
| Novartis Pharmaceuticals Corporation | $537.77 | 2021-2025 | |
| Galderma Laboratories, L.P. | $532.17 | 2021-2025 | Nemluvio, Aklief |
| Organogenesis INC. | $452.52 | 2021-2025 | Nushield, Novachor, Affinity |
| Amgen INC. | $318.28 | 2021-2025 | Otezla, Otezla |
| Mayne Pharma Commercial LLC | $292.69 | 2021-2022 | |
| Incyte Corporation | $281.17 | 2021-2023 | Opzelura |
| Genzyme Corporation | $258.28 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $254.81 | 2021-2025 | Dupixent, Libtayo |
| Pfizer INC. | $221.07 | 2021-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $180.03 | 2023-2025 | Zoryve |
| Journey Medical Corporation | $172.50 | 2021-2023 | |
| Leo Pharma INC. | $165.72 | 2021-2023 | Adbry |
| Almirall LLC | $159.41 | 2021-2024 | Seysara |
| Ucb, INC. | $115.84 | 2021-2025 | Bimzelx |
| Vyne Pharmaceuticals INC. | $97.85 | 2021 | |
| Genentech USA, INC. | $46.76 | 2021-2023 | Erivedge |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $42.55 | 2021-2023 | Arazlo |
| Acera Surgical, INC. | $41.51 | 2021-2022 | |
| Verrica Pharmaceuticals INC. | $29.28 | 2023-2024 | Ycanth |
| Organon LLC | $24.11 | 2025 | Vtama |
| Reprise Biomedical, INC. | $22.48 | 2025 | Miro3d |
| Fresenius Kabi USA, LLC | $19.44 | 2023 | Idacio |
| Biofrontera INC. | $18.74 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Dermira, INC. | $16.72 | 2021 | |
| Nabriva Therapeutics, Plc | $14.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.